These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 20673728

  • 1. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones.
    Ortqvist P, Gising J, Ehrenberg AE, Vema A, Borg A, Karlén A, Larhed M, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Sep 01; 18(17):6512-25. PubMed ID: 20673728
    [Abstract] [Full Text] [Related]

  • 2. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
    Ortqvist P, Peterson SD, Kerblom E, Gossas T, Sabnis YA, Fransson R, Lindeberg G, Helena Danielson U, Karlén A, Sandström A.
    Bioorg Med Chem; 2007 Feb 01; 15(3):1448-74. PubMed ID: 17113777
    [Abstract] [Full Text] [Related]

  • 3. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 4. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Jul 15; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 5. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX, Vibulbhan B, Yang W, Nair LG, Tong X, Cheng KC, Njoroge FG.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1105-9. PubMed ID: 19168351
    [Abstract] [Full Text] [Related]

  • 6. Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.
    Gising J, Belfrage AK, Alogheli H, Ehrenberg A, Åkerblom E, Svensson R, Artursson P, Karlén A, Danielson UH, Larhed M, Sandström A.
    J Med Chem; 2014 Mar 13; 57(5):1790-801. PubMed ID: 23517538
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 9. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY, Lu CS, Lin TH.
    J Mol Graph Model; 2008 Apr 11; 26(7):1131-44. PubMed ID: 18024210
    [Abstract] [Full Text] [Related]

  • 10. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M, Bailey MD, Ghiro E, Gorys V, Halmos T, Poirier M, Rancourt J, Goudreau N.
    J Med Chem; 2004 Dec 16; 47(26):6584-94. PubMed ID: 15588093
    [Abstract] [Full Text] [Related]

  • 11. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 16; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 12. P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
    Lampa A, Ehrenberg AE, Vema A, Åkerblom E, Lindeberg G, Danielson UH, Karlén A, Sandström A.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4917-27. PubMed ID: 21782454
    [Abstract] [Full Text] [Related]

  • 13. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J, Lemke C, Goudreau N, Beaulieu E, White PD, Llinàs-Brunet M, Forgione P.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3400-4. PubMed ID: 18448339
    [Abstract] [Full Text] [Related]

  • 14. A straightforward microwave method for rapid synthesis of N-1, C-6 functionalized 3,5-dichloro-2(1H)-pyrazinones.
    Gising J, Ortqvist P, Sandström A, Larhed M.
    Org Biomol Chem; 2009 Jul 07; 7(13):2809-15. PubMed ID: 19532999
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design, synthesis, and biological activity of m-tyrosine-based 16- and 17-membered macrocyclic inhibitors of hepatitis C virus NS3 serine protease.
    Chen KX, Njoroge FG, Pichardo J, Prongay A, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2005 Oct 06; 48(20):6229-35. PubMed ID: 16190750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V.
    Ortqvist P, Vema A, Ehrenberg AE, Dahl G, Rönn R, Akerblom E, Karlén A, Danielson UH, Sandström A.
    Antivir Ther; 2010 Oct 06; 15(6):841-52. PubMed ID: 20834096
    [Abstract] [Full Text] [Related]

  • 19. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
    Ding CZ, Zhang YK, Li X, Liu Y, Zhang S, Zhou Y, Plattner JJ, Baker SJ, Liu L, Duan M, Jarvest RL, Ji J, Kazmierski WM, Tallant MD, Wright LL, Smith GK, Crosby RM, Wang AA, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7317-22. PubMed ID: 21067923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.